BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 16, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 5/13 cls
Agenus Inc. (NASDAQ:AGEN) Rodman Reni Benjamin Upgrade Market outperform (from marlet perform) 2% $0.93
Benjamin also set a target of $2. He believes QS-21 Stimulon adjuvant represents a significant asset that is below the radar of most investors. The adjuvant is in multiple Phase III trials in combination with vaccines, including a herpes zoster and the Mosquirix malaria vaccine fromGlaxoSmithKline plc (LSE:GSK; NYSE:GSK). He anticipates Phase III data next half or in 1H12.
Alkermes Inc. (NASDAQ:ALKS) Leerink Steve Yoo Upgrade Market outperform (from market perform) 23% $17.76
Yoo also raised his target to $16-$19 from...

Read the full 766 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >